Heit JA. Epidemiology of venous thromboembolism. Nat Rev Cardiol. 2015;12:464–74.

Article  PubMed  PubMed Central  Google Scholar 

Cohen AT, Agnelli G, Anderson FA, Arcelus JI, Bergqvist D, Brecht JG, et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost. 2007;98:756–64.

Article  PubMed  CAS  Google Scholar 

Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing G-J, Harjola V-P, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). 2019;54:1901647.

Google Scholar 

Mazzolai L, Aboyans V, Ageno W, Agnelli G, Alatri A, Bauersachs R, et al. Diagnosis and management of acute deep vein thrombosis: a joint consensus document from the European Society of Cardiology working groups of aorta and peripheral vascular diseases and pulmonary circulation and right ventricular function. Eur Heart J. 2017;39:4208–18.

Article  Google Scholar 

Stevens SM, Woller SC, Baumann Kreuziger L, Bounameaux H, Doerschug K, Geersing G-J, et al. Executive Summary: Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report. Chest. 2021;160:2247–59.

Article  PubMed  Google Scholar 

Lyman GH, Carrier M, Ay C, Di Nisio M, Hicks LK, Khorana AA, et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv. 2021;5:927–74.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Falanga A, Ay C, Di Nisio M, Gerotziafas G, Jara-Palomares L, Langer F, et al. Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline. Ann Oncol. 2023;34:452–67.

Article  PubMed  CAS  Google Scholar 

Mearns ES, Kohn CG, Song JS, Hawthorne J, Meng J, White CM, et al. Meta-analysis to assess the quality of international normalized ratio control and associated outcomes in venous thromboembolism patients. Thromb Res. 2014;134:310–9.

Article  PubMed  CAS  Google Scholar 

Oake N, Jennings A, Forster AJ, Fergusson D, Doucette S, van Walraven C. Anticoagulation intensity and outcomes among patients prescribed oral anticoagulant therapy: a systematic review and meta-analysis. CMAJ. 2008;179:235–44.

Article  PubMed  PubMed Central  Google Scholar 

Rodriguez RA, Carrier M, Wells PS. Non-adherence to new oral anticoagulants: a reason for concern during long-term anticoagulation? J Thromb Haemost. 2013;11:390–4.

Article  PubMed  CAS  Google Scholar 

Speed V, Auyeung V, Patel JP, Cooper D, Miller S, Roberts LN, et al. Adherence to rivaroxaban for the treatment of venous thromboembolism-Results from the FIRST registry. Res Pract Thromb Haemost. 2021;5: e12614.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Alberts M, Zhdanava M, Pilon D, Caron-Lapointe G, Lefebvre P, Bookhart B, et al. Venous Thromboembolism Recurrence Among Patients Who Abandon Oral Anticoagulant Therapy in the USA: A Retrospective Longitudinal Study. Adv Ther. 2023;40:1750–64.

Article  PubMed  PubMed Central  Google Scholar 

Ageno W, Samperiz A, Caballero R, Dentali F, Di Micco P, Prandoni P, et al. Duration of anticoagulation after venous thromboembolism in real world clinical practice. Thromb Res. 2015;135:666–72.

Article  PubMed  CAS  Google Scholar 

de Winter MA, Remme GCP, Kaasjager K, Nijkeuter M. Short-term versus extended anticoagulant treatment for unprovoked venous thromboembolism: A survey on guideline adherence and physicians’ considerations. Thromb Res. 2019;183:49–55.

Article  PubMed  Google Scholar 

Wallace R, Anderson MA, See K, Gorelik A, Irving L, Manser R. Venous thromboembolism management practices and knowledge of guidelines: a survey of Australian haematologists and respiratory physicians. Intern Med J. 2017;47:436–46.

Article  PubMed  Google Scholar 

Ten Cate V, Prins MH. Secondary prophylaxis decision-making in venous thromboembolism: interviews on clinical practice in thirteen countries. Res Pract Thromb Haemost. 2017;1:41–8.

Article  PubMed  PubMed Central  Google Scholar 

Kripalani S, Risser J, Gatti ME, Jacobson TA. Development and evaluation of the Adherence to Refills and Medications Scale (ARMS) among low-literacy patients with chronic disease. Value Health. 2009;12:118–23.

Article  PubMed  Google Scholar 

Eliquis : EPAR - Product Information. https://www.ema.europa.eu/en/medicines/human/EPAR/eliquis# . Accessed 08 Jan 2025.

Xarelto : EPAR - Product Information. https://www.ema.europa.eu/en/medicines/human/EPAR/xarelto . Accessed 08 Jan 2025.

Allahwerdy F, Pan S, Feehan M, Jones AE, Munger MA, Witt DM. A descriptive study of antithrombotic medication patterns in adult patients with recent venous thromboembolism. Pharm Pract (Granada). 2019;17:1539.

Article  PubMed  Google Scholar 

Haas S, Ageno W, Weitz JI, Goldhaber SZ, Turpie AGG, Goto S, et al. Anticoagulation therapy patterns for acute treatment of venous thromboembolism in GARFIELD-VTE patients. J Thromb Haemost. 2019;17:1694–706.

Article  PubMed  CAS  Google Scholar 

Ioannou P, Kladou E. Anticoagulation management in deep venous thrombosis - real world data and unmet needs. Hippokratia. 2019;23:144.

PubMed  PubMed Central  CAS  Google Scholar 

Antonucci E, Migliaccio L, Abbattista M, Caronna A, De Marchi S, Di Giorgio A, et al. Treatment Decision-Making of Secondary Prevention After Venous Thromboembolism: Data From the Real-Life START2-POST-VTE Register. Clin Appl Thromb Hemost. 2020. https://doi.org/10.1177/1076029620945792.

Article  PubMed  PubMed Central  Google Scholar 

Cohen AT, Gitt AK, Bauersachs R, Fronk EM, Laeis P, Mismetti P, et al. The management of acute venous thromboembolism in clinical practice. Results from the European PREFER in VTE Registry. Thromb Haemost. 2017;117:1326–37.

Article  PubMed  PubMed Central  Google Scholar 

Ghanima W, Schultze A, Donaldson R, Brodin E, Halvorsen S, Graham S, et al. Oral Anticoagulation Therapy for Venous Thromboembolism in Norway: Time Trends and Treatment Patterns. Clin Ther. 2021;43:1179-90.e3.

Article  PubMed  CAS  Google Scholar 

Iyer GS, Tesfaye H, Khan NF, Zakoul H, Bykov K. Trends in the Use of Oral Anticoagulants for Adults With Venous Thromboembolism in the US, 2010–2020. JAMA Netw Open. 2023;6: e234059.

Article  PubMed  PubMed Central  Google Scholar 

Ramagopalan SV, Carroll R, Ulvestad M, Mehmud F, Alikhan R. The changing face of venous thromboembolism management in England. Future Cardiol. 2019;15:183–5.

Article  PubMed  CAS  Google Scholar 

European Pharmaceutical Review. Bayer’s Xarelto® approved in the EU for the prevention of stroke in patients (20 December 2011). https://www.europeanpharmaceuticalreview.com/news/10555/bayers-xarelto-approved-in-the-eu-for-the-prevention-of-stroke-in-patients-with-af/ . Accessed 08 Jan 2025.

Pfizer. European Commission Approves Eliquis (apixaban) for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and Prevention of Recurrent DVT and PE (Press release, 29 July 2014). https://www.pfizer.com/news/press-release/press-release-detail/european_commission_approves_eliquis_apixaban_for_the_treatment_of_deep_vein_thrombosis_dvt_and_pulmonary_embolism_pe_and_prevention_of_recurrent_dvt_and_pe . Accessed 08 Jan 2025.

Johnson & Johnson. FDA Approves XARELTO® (rivaroxaban) to Treat Deep Vein Thrombosis and Pulmonary Embolism, and to Reduce the Risk of Recurrent Events (Press release, 02 November 2012). https://www.jnj.com/media-center/press-releases/fda-approves-xarelto-rivaroxaban-to-treat-deep-vein-thrombosis-and-pulmonary-embolism-and-to-reduce-the-risk-of-recurrent-events . Accessed 08 Jan 2025.

Pfizer. U.S. FDA Approves Eliquis (apixaban) for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and for the Reduction in the Risk of Recurrent DVT and PE Following Initial Therapy (Press release, 21 August 2014). https://www.pfizer.com/news/press-release/press-release-detail/u_s_fda_approves_eliquis_apixaban_for_the_treatment_of_deep_vein_thrombosis_dvt_and_pulmonary_embolism_pe_and_for_the_reduction_in_the_risk_of_recurrent_dvt_and_pe_following_initial_therapy . Accessed 08 Jan 2025.

Keller L, Marten S, Hecker J, Sahin K, Tittl L, Beyer-Westendorf J. Venous thromboembolism therapy with rivaroxaban in daily-care patients: Results from the Dresden NOAC registry. Int J Cardiol. 2018;257:276–82.

Article  PubMed  Google Scholar 

Williams M, Ahuja T, Raco V, Papadopoulos J, Green D, Yuriditsky E, et al. Real world prescribing practices of apixaban or rivaroxaban lead-in doses for the treatment of venous thromboembolism in hospitalized patients. J Thromb Thrombolysis. 2022;54:219–29.

Article  PubMed  CAS  Google Scholar 

Trujillo-Santos J, Di Micco P, Dentali F, Douketis J, Díaz-Peromingo JA, Núñez MJ, et al. Real-life treatment of venous thromboembolism with direct oral anticoagulants: The influence of recommended dosing and regimens. Thromb Haemost. 2017;117:382–9.

Article  PubMed  Google Scholar 

Saunders JA, Gustafson WL, Vazquez SR, Jones AE, Witt DM. Rea